Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell save search
Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2022-03-09 (Crawled : 02:00) - globenewswire.com
CRBU | $3.8 -2.81% 1.2M
|
Health Technology
|
| O: 4.28%
H: 5.05%
C: 2.74%
cb-011 america car-t research cel preclinical therapy bioscience cancer t-cell pre-clinical
Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022
Published: 2022-03-08 (Crawled : 00:00) - globenewswire.com
BMEA | $10.63 -4.75% 460K
|
Professional, Scientific, and T...
|
| O: 3.25%
H: 4.04%
C: 2.25%
bmf-219 solid tumors presentation cel preclinical t-cell pre-clinical
Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022
Published: 2022-03-08 (Crawled : 23:00) - prnewswire.com
ACLX | $51.62 -5.28% 250K
|
|
| O: 2.8%
H: 3.41%
C: -6.98%
aclx-002 america myeloid leukemia car-t leukemia research presentation cel pre-clinical therapy cancer t-cell preclinical acute myeloid leukemia
Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
Published: 2022-03-08 (Crawled : 22:00) - globenewswire.com
SANA | $7.41 -4.14% 1.2M
|
|
| O: 3.73%
H: 6.92%
C: 5.94%
america technology research cel preclinical cancer biotech iot t-cell pre-clinical
TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells
Published: 2022-03-08 (Crawled : 17:00) - biospace.com/
TCBP | $1.46 2.82% 73K
|
|
| O: 8.36%
H: 12.75%
C: -5.38%
myeloid leukemia pos phase 1b leukemia cel phase 1 positive t-cell acute myeloid leukemia phase 2b
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
Published: 2022-03-02 (Crawled : 01:00) - prnewswire.com
KPTI | $1.255 -1.95% 620K
|
Health Technology
|
| O: -28.03%
H: 1.74%
C: -16.2%
xpovio treatment approval cel t-cell
Long term study confirms efficacy of ISA Pharmaceuticals' T-cell activating immunotherapy in combination with checkpoint inhibitor
Published: 2022-03-01 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -3.33%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
als long term cel immunotherapy therapy t-cell
U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen's First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-03-01 (Crawled : 02:00) - prnewswire.com
JNJ | News | $147.6 1.28% 5.6M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
treatment fda car-t cel immunotherapy therapy
BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer
Published: 2022-02-21 (Crawled : 19:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.59%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -1.26%
H: 0.81%
C: 0.46%
BNTX | $87.13 1.11% 350K
|
Health Technology
|
| O: -4.75%
H: 3.0%
C: 0.27%
cel collaboration cancer t-cell immunotherapy
Innovent Announces First Patient Dosing of Universal "Modular" CAR-T Cell product IBI345
Published: 2022-02-21 (Crawled : 01:00) - prnewswire.com
INCY | $52.07 -1.42% 800K
|
Health Technology
| Email alert
Add to watchlist
LLY | $727.48 -2.48% 2M
|
Health Technology
| Email alert
Add to watchlist
ibi345 car-t cel t-cell
Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease
Published: 2022-02-18 (Crawled : 17:00) - globenewswire.com
ADPT | $2.405 3.0% 1.1M
|
Commercial Services
|
| O: -0.77%
H: 1.76%
C: -4.73%
immunoseq technology disease cel biotech iot t-cell
VIDEO: Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Published: 2022-02-17 (Crawled : 22:00) - poseida.com
PSTX | News | $1.98 -1.0% 350K
|
Health Technology
|
| O: 0.0%
H: 0.95%
C: -15.2%
psma-101 prostate cancer state car-t cel phase 1 cancer phase 2 t-cell
Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Published: 2022-02-17 (Crawled : 20:00) - poseida.com
PSTX | News | $1.98 -1.0% 350K
|
Health Technology
|
| O: -2.24%
H: 15.34%
C: 12.61%
psma-101 prostate cancer state car-t cel phase 1 cancer phase 2 t-cell
Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma
Published: 2022-02-17 (Crawled : 14:00) - biospace.com/
GRCL | $10.25 -0.29% 6.4M
|
Manufacturing
|
| O: 0.53%
H: 2.65%
C: -5.82%
gc012 car-t trial cel therapy biotech iot t-cell
Regulatory T-cells (Tregs) Therapies Market - Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot
Published: 2022-02-16 (Crawled : 08:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.52%
H: 1.83%
C: 1.24%
NKTR | $1.23 -6.82% 1.7M
|
Health Technology
|
| O: -0.27%
H: 1.26%
C: 0.36%
trial cel t-cell therapy
Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors
Published: 2022-02-15 (Crawled : 23:00) - biospace.com/
CSBR | $5.1 0.69% 790
|
Health Technology
|
| O: 2.2%
H: 8.09%
C: 4.18%
react partnership cel active t-cell
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium
Published: 2022-02-15 (Crawled : 14:00) - biospace.com/
MBIO | $0.36 -2.97% 68K
|
Health Technology
|
| O: 1.69%
H: 5.15%
C: 5.15%
FBIO | $1.75 -3.32% 150K
|
Health Technology
|
| O: 1.09%
H: 2.15%
C: 1.08%
mb-105 america symposium state presentation cel stem cell cancer
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.07 -1.42% 800K
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.07 -1.42% 800K
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
Global Cell & Gene Therapy Market Research Report 2022: Expanding Application for Cell & Gene Therapies & Growing Demand for CAR T- Cell Therapies
Published: 2022-02-01 (Crawled : 21:00) - prnewswire.com
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: -0.53%
H: 0.21%
C: -0.07%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: 0.0%
ema application gene therapy research cel gene therapies report therapy growing t-cell
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.